Streetbeat News

Equity Actions

CC

OKTA

SNOW

PCE data matched forecasts, influencing market sentiment. Okta's stock surged due to optimistic future guidance, while Snowflake's shares fell. Chemours experienced a decline after announcing executive changes and a delay in filing its 10-K report.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 3:10 pm

CC

Chemours shares dropped following the announcement of executive changes and the delay of its fourth quarter results and 10-K filing.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 3:04 pm

HLLY

Holley (NYSE:HLLY) was analyzed by 4 analysts, showing a mix of bullish to indifferent sentiments with no bearish views. The average 12-month price target is $7.75, with a high of $9.00 and a low of $5.00. Analyst actions include both maintaining and lowering ratings, with price targets adjusted accordingly. Holley, a designer and manufacturer of high-performance automotive aftermarket products, shows positive revenue growth but faces challenges in profitability, debt management, and capital utilization.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 3:01 pm

ADMA

Analyst ratings for ADMA Biologics (NASDAQ:ADMA) show a mix of bullish to bearish sentiments, with a recent trend towards more bullish projections. The average 12-month price target is now $6.75, up from $6.00, indicating a positive outlook. Key financial indicators reveal strong revenue growth, profitability, and financial health, despite a high debt-to-equity ratio. The company specializes in plasma-derived biologics for immunodeficient patients.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 3:01 pm

ALKT

Alkami Technology (NASDAQ:ALKT) received mixed analyst ratings with an average 12-month price target of $27.12, reflecting a 17.05% increase from the previous target. The company showed a revenue growth of 26.76% as of September 30, 2023, but struggles with a net margin of -22.86% and an ROA of -3.24%. Despite these challenges, Alkami's ROE outperforms industry averages at -4.8%, and it maintains a low debt-to-equity ratio of 0.32.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 3:00 pm

ACMR

ACM Research (NASDAQ:ACMR) has seen varied analyst ratings over the past three months, with a recent shift towards more bullish perspectives. The average 12-month price target for ACMR has been raised to $28.02, marking a 23.44% increase from the previous target. Analysts from Benchmark, Needham, Goldman Sachs, Roth MKM, and Needham have adjusted their ratings and price targets, reflecting optimism about ACMR's market position and financial health. The company's revenue growth, net margin, ROE, ROA, and debt management are highlighted as key financial strengths.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 3:00 pm

BLBD

Blue Bird (NASDAQ:BLBD) received mixed analyst ratings with 3 bullish and 1 somewhat bullish in the past three months. The average 12-month price target is $38.0, reflecting a 34.13% increase from the previous $28.33. Analysts from Needham, Barclays, Roth MKM, and Craig-Hallum have adjusted their ratings and price targets, indicating a positive outlook based on Blue Bird's financial performance, including a notable revenue growth of 34.75%, a net margin of 8.23%, and an ROE of 45.25%. However, the company's debt-to-equity ratio of 1.8 suggests higher financial risk.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 3:00 pm

PRST

Presto Automation has announced a registered direct offering of 8,533,000 shares, priced at $0.25 per share, aiming to raise approximately $2.1 million. This move could indicate the company's need for capital, potentially for expansion or operational purposes.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 2:44 pm

BBWI

Bath & Body Works, Inc. (NYSE:BBWI) shares fell after reporting Q4 earnings and a modest outlook for Q1 and FY24. Despite beating Q4 earnings and revenue estimates, the company's forecast for net sales and EPS for the full year and Q1 2024 is below consensus estimates. BBWI also announced a new $500 million share repurchase program.

Portfolio Pulse from Nabaparna Bhattacharya

February 29, 2024 | 2:27 pm

AUPH

Aurinia Pharmaceuticals Inc. has been granted exemptive relief by Canadian securities regulators, allowing the company to proceed with its share repurchase program. This decision enables Aurinia to buy back shares under certain conditions, potentially impacting its stock price positively in the short term due to the reduced supply of shares and increased investor confidence.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 2:10 pm